Cell & Gene Insights Fast Facts: Is Bigger Better in Viral Vector Manufacturing?
Cell ; gene therapy (C ;GT) is complex, expensive and lacks standardization.
How do you effectively evaluate and make informed decisions to identify a winning viral vector production strategy to improve the accessibility ; affordability of C ;GT?
We are thrilled to announce our Fast Facts video with Cell ; Gene Insights, where our expert Andrea Vervoort, Technical Lead, breaks down key cost drivers of AAV manufacturing and the commercial impacts of incorporating Virica’s Viral Sanitizers (VSE TM ) using Biopharm’s BioSolve Bioprocess modelling.
Click here to view our latest bioprocess modelling data in a Fast Facts video on Cell ; Gene Insights!
The post Cell & Gene Insights Fast Facts: Is Bigger Better in Viral Vector Manufacturing? appeared first on Virica Biotech .
Full content in Virica Biotech